Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
07. November 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data...
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
30. Oktober 2024 16:30 ET
|
Cardiff Oncology, Inc.
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis...
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
08. August 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP...
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
01. August 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology to Present at the Jefferies Healthcare Conference
29. Mai 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
13. Mai 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
06. März 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
29. Februar 2024 16:07 ET
|
Cardiff Oncology, Inc.
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data...
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
29. Februar 2024 16:06 ET
|
Cardiff Oncology, Inc.
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - -...
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
29. Februar 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the...